WTW population health leader Jeff Levin-Scherz on what brokers must do before 2027 renewals
Healthcare costs for US employers are on track to rise 11.1 percent in 2027 without plan changes - the steepest projected increase in roughly two decades - and even employers that act aggressively can expect a 9.5 percent jump, according to WTW's 2026 Best Practices in Healthcare Survey of 471 US employers.
The findings land at the worst possible moment: 62 percent of employers were already over budget in 2025, exceeding their targets by an average of 5.6 percentage points, and 78 percent say they are experiencing more financial pressure from healthcare costs than at any point in the past decade.
In an interview with Insurance Business Benefits US, Jeff Levin-Scherz, population health leader at WTW, says the forces pushing costs upward are structural and unlikely to ease in the near term.
"Medical costs have increased due to a combination of structural issues," he said. "The first is innovation - we are buying huge advances in oncology and treatment of inflammatory diseases, and these cost more. The second is general inflation. Medical providers are paying more for labor and supplies, just like other businesses. The third is provider consolidation.
There are essentially no markets with robust hospital competition, and in the commercial market the health plans are fragmented and none has the leverage to insist on lower prices."
The survey reinforces that view: 80 percent of employers expect elevated healthcare costs for at least the next three years, and 65 percent expect the pressure to persist for five years or more. Compare that to wage growth hovering around 3.5 percent, and the squeeze facing plan sponsors becomes clear.
## A cost-shift that carries workforce risk
The financial pressure is forcing a reckoning for employer plan sponsors. By 2028, 85 percent of employers are planning or considering raising employee premium contributions, up from 44 percent today, according to WTW.
Out-of-pocket cost increases are following the same trajectory, rising from 30 percent of employers in 2023 to a projected 71 percent by 2028. Levin-Scherz warns that the cumulative effect of these shifts carries a risk many plan sponsors are underestimating.
"Employers are in a difficult position because changes in plan design yield early and certain savings, and many other interventions take a long time to mature and have significant execution risk," he said.
Levin-Scherz pointed to a Commonwealth Fund study - The State of Health Insurance Coverage in 2026, published October 22, 2026 - that documents high rates of underinsurance, including among workers with employer-sponsored coverage.
The study found that 23 percent of adults aged 19–64 were insured all year but underinsured, and 11 percent were uninsured.
"Employers should do analytics to determine what a change in plan design will mean for lower-wage employees - and how many would be likely to face financial insecurity due to medical costs," he said.
For benefits advisors working the 2027 renewal, that means reframing cost-shifting conversations with employer clients as a workforce and retention risk analysis, not simply a budgeting exercise. Brokers looking to understand how employer cost-sharing decisions are reshaping group health plan design can draw on a growing body of IBB analysis covering benefit plan trends and renewal tactics.
## The vendor measurement gap
The survey also reveals a troubling disconnect in how employers evaluate the point solutions they deploy. The average employer now works with 13 health and wellbeing vendors - down from a peak of 14 in 2025, suggesting early signs of consolidation, but still well above the 11 vendors recorded in 2022.
Despite that growth, only 34 percent evaluate the clinical impact of their programs and only 42 percent the financial impact, per WTW's data. In other words, most employers cannot fully answer whether the vendors they are paying for are working.
Levin-Scherz, who brings both a physician's perspective and benefits strategy expertise to the question, was direct. "Clearly, employers should do rigorous measurement to be sure that their vendor programs are delivering value," he said. "Many vendor ROI analytics are deeply flawed, so employers should seek an outside party to review program effectiveness."
The same scrutiny is extending to pharmacy benefit managers (PBMs).
Employer satisfaction with PBMs has deteriorated sharply: the Net Promoter Score for PBMs fell from −10 in 2024 to −25 in 2026, with confidence that a PBM secures the most advantageous pricing dropping 15 percentage points, from 54 percent to 39 percent.
As a result, 64 percent of employers are already taking or planning concrete action on their PBM relationships - including taking contracts out to bid and assessing independent PBMs. Brokers advising mid-market clients on vendor consolidation and pharmacy benefit manager contract review strategies are increasingly positioned as the analytical layer employers lack internally.
## GLP-1s and specialty drugs: the pharmacy pressure point
Pharmacy benefits - particularly specialty drugs and glucagon-like peptide-1 (GLP-1) medications - now represent roughly one-quarter of total employer healthcare spending, and when drugs administered through medical benefits are included, WTW estimates pharmaceutical spending reaches approximately 36 percent of total healthcare claims. The figure has made pharmacy benefit management a frontline issue in every renewal conversation.
GLP-1 coverage is becoming one of the most consequential decisions employers face heading into 2027. For the first time in three years, the share of employers covering GLP-1s for weight loss has declined, dropping from 56 percent to 53 percent.
The trend beneath that headline is more telling: employers with coverage in place and planning to keep it fell from 48 percent to 37 percent year over year, while those considering removal nearly doubled, from nine percent to 16 percent.
Among employers pulling back, cost is the overwhelming driver, cited by 91 percent.
Levin-Scherz outlined several levers available to employers and their advisors. On GLP-1s: "Prices direct to consumers are lower, so employers can maintain coverage by subsidizing direct purchase. That's hard for lower-wage workers though, and these expenses are not applied to deductible or out-of-pocket maximum."
He noted that employers often add program participation requirements to focus coverage on the most committed users - and WTW's data shows this approach produces better clinical outcomes, with employees facing restrictions nearly twice as likely to reduce their body mass index by 10 or more points compared with those without them.
For other specialty drugs - which already drive roughly half of total pharmacy cost - he pointed to biosimilars as a significant savings opportunity.
PBMs "sometimes prefer their own biosimilar drugs which cost much more than other drugs," he said, adding that changing the site of service to avoid large outpatient hospital fees and drug markups can also yield meaningful savings. WTW's survey projects that employer efforts to influence specialty pharmacy site of care will jump from 25 percent today to 57 percent by 2028 as a growing set of vendor options makes action more feasible.
Brokers advising plan sponsors on specialty pharmacy cost management and site-of-care strategies for group health plans should note: the lever most underused may simply be independent scrutiny of what the PBM is actually recommending.
## Legislative relief: possible but not imminent
Adding to the voices contemplating the impact of the November 2026 midterm election results, Levin-Sherz does not see a magic fix for high health plan costs.
"No one should expect that the midterm election results will lead to rapid relief from high rates of medical inflation," he said.
He noted that expiring subsidies for Affordable Care Act (ACA) marketplace plans and coming Medicaid cuts could actually push costs higher for employer-sponsored plans by reducing the financial stability of safety-net hospitals.
Some relief may come from state action. Indiana and Delaware have passed legislation that would limit hospital bills to a multiple of the Medicare fee schedule - a model that could produce meaningful savings for employer-sponsored plans if adopted more broadly. At the federal level, he sees potential for bipartisan legislation to regulate PBMs and carriers, and to address high arbitration awards under the No Surprises Act.
The Centers for Medicare & Medicaid Services (CMS) has published detailed No Surprises Act guidance for employer group health plans that brokers and plan sponsors should review ahead of 2027 renewals.
"These changes won't solve our medical cost crisis," Levin-Scherz said, "but they will help."
Free newsletter
We'll keep you up-to-date with the latest breaking news, cutting edge opinion, and expert analysis affecting both your business and the industry as whole.
Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by Finopulse.
Publisher: Source link